Here's how Pfizer’s reorg and Mylan’s identity crisis yielded a giant generics merger

29th October 2019 Uncategorised 0

Last July, Pfizer decided to reorganize and lumped off-patent drugs into an autonomous unit. A month later, Mylan launched a strategic review to appease restive shareholders. Once the two companies realized they had common ground—and Pfizer CEO Albert Bourla made a well-timed phone call—they struck a deal in less than 90 days.

More: Here's how Pfizer’s reorg and Mylan’s identity crisis yielded a giant generics merger
Source: fierce